Risk Stratification and Treatment of Obesity for Primary and Secondary Prevention of Cardiovascular Disease

IF 5.7 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Atherosclerosis Reports Pub Date : 2023-12-30 DOI:10.1007/s11883-023-01182-3

John W. Ostrominski, Tiffany M. Powell-Wiley

{"title":"Risk Stratification and Treatment of Obesity for Primary and Secondary Prevention of Cardiovascular Disease","authors":"John W. Ostrominski, Tiffany M. Powell-Wiley","doi":"10.1007/s11883-023-01182-3","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>In this review, we discuss contemporary and emerging approaches for risk stratification and management of excess adiposity for the primary and secondary prevention of cardiovascular disease.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Obesity is simultaneously a pandemic-scale disease and major risk factor for the incidence and progression of a wide range of cardiometabolic conditions, but risk stratification and treatment remain clinically challenging. However, sex-, race-, and ethnicity-sensitive anthropometric measures, body composition–focused imaging, and health burden–centric staging systems have emerged as important facilitators of holistic risk prediction. Further, expanding therapeutic approaches, including comprehensive lifestyle programs, anti-obesity pharmacotherapies, device/endoscopy-based interventions, metabolic surgery, and novel healthcare delivery resources offer new empowerment for cardiovascular risk reduction in individuals with obesity.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Personalized risk stratification and weight management are central to reducing the lifetime prevalence and impact of cardiovascular disease. Further evidence informing long-term safety, efficacy, and cost-effectiveness of novel approaches targeting obesity are critically needed.</p>","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"38 1","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-023-01182-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of Review

In this review, we discuss contemporary and emerging approaches for risk stratification and management of excess adiposity for the primary and secondary prevention of cardiovascular disease.

Recent Findings

Obesity is simultaneously a pandemic-scale disease and major risk factor for the incidence and progression of a wide range of cardiometabolic conditions, but risk stratification and treatment remain clinically challenging. However, sex-, race-, and ethnicity-sensitive anthropometric measures, body composition–focused imaging, and health burden–centric staging systems have emerged as important facilitators of holistic risk prediction. Further, expanding therapeutic approaches, including comprehensive lifestyle programs, anti-obesity pharmacotherapies, device/endoscopy-based interventions, metabolic surgery, and novel healthcare delivery resources offer new empowerment for cardiovascular risk reduction in individuals with obesity.

Summary

Personalized risk stratification and weight management are central to reducing the lifetime prevalence and impact of cardiovascular disease. Further evidence informing long-term safety, efficacy, and cost-effectiveness of novel approaches targeting obesity are critically needed.

Abstract Image

查看原文本刊更多论文

为心血管疾病的一级和二级预防进行风险分层和肥胖症治疗

最新研究结果肥胖既是一种大范围流行的疾病，也是多种心血管代谢疾病发生和发展的主要风险因素，但风险分层和治疗在临床上仍具有挑战性。然而，对性别、种族和民族敏感的人体测量方法、以身体成分为重点的成像技术以及以健康负担为中心的分期系统已成为全面风险预测的重要促进因素。此外，不断扩展的治疗方法，包括综合生活方式计划、抗肥胖药物治疗、基于设备/内窥镜的干预、代谢手术和新型医疗保健服务资源，为降低肥胖症患者的心血管风险提供了新的手段。摘要个性化风险分层和体重管理是降低心血管疾病终生患病率和影响的核心。我们亟需进一步的证据来证明针对肥胖症的新方法的长期安全性、有效性和成本效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.